Eidd-2801 Medchemexpress

EIDD-2801
10-024 50 mg
EUR 440.88
Description: EIDD-2801 is an orally bioavailable prodrug of the antiviral nucleoside derivative N4-hydroxycytidine (NHC, EIDD-1931). It is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). The compound interferes with the action of viral RNA polymerase. It exerts its antiviral action through introduction of copying errors during viral RNA replication. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. The broad-spectrum antiviral agent EIDD-2801 inhibits viral RNA replication in various unrelated RNA viruses including influenza, Ebola, Venezuelan equine encephalitis virus (VEEV) and coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2. EIDD-2801 has the potential for COVID-19, seasonal and pandemic influenza treatment.

Human IgG antibody Laboratories manufactures the eidd-2801 medchemexpress reagents distributed by Genprice. The Eidd-2801 Medchemexpress reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact MedChemExpress Inc.. Other Eidd-2801 products are available in stock. Specificity: Eidd-2801 Category: Medchemexpress

EIDD-2801
10
EUR 110.2

EIDD-2801
50
EUR 216.3

EIDD 2801
100mg
EUR 230
Description: 2349386-89-4

EIDD-2801
10mg
EUR 660

EIDD-2801
5mg
EUR 430

EIDD-2801
5x10mg
EUR 2650

EIDD-2801
100mg
EUR 310

Chemicals information

EIDD-1931
HY-125033 50mg
EUR 378.79
Description: EIDD-1931 (Beta-d-N4-hydroxycytidine; NHC) is a novel nucleoside analog and behaves as a potent anti-virus agent. EIDD-1931 effectively inhibits the replication activity of venezuelan equine encephalitis virus (VEEV), Chikungunya virus (CHIKV) and hepatitis C virus (HCV)[1].

EIDD-2749
HY-146246 10 mg
EUR 1948.08
Description: EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses[1][2][3].

EIDD 2801-D7
E985797 10mg
EUR 873

EIDD-1931-d2
HY-125033S1 1mg Ask for price
Description: EIDD-1931-d2 is the deuterium labeled 3,6-Dichloro-2-methoxybenzoic acid[1].

Eidd 1931
E985800 100mg
EUR 873
Description: 496036

EIDD-1931
555756 100.0mg
EUR 150

EIDD-1619
MBS5781211-5mg 5(mg
EUR 915

EIDD-1619
MBS5781211-5x5mg 5x5(mg
EUR 3970

EIDD-1931
T8498-10mg 10mg Ask for price
Description: EIDD-1931

EIDD-1931
T8498-1g 1g Ask for price
Description: EIDD-1931

EIDD-1931
T8498-1mg 1mg Ask for price
Description: EIDD-1931

EIDD-1931
T8498-50mg 50mg Ask for price
Description: EIDD-1931

EIDD-1931
T8498-5mg 5mg Ask for price
Description: EIDD-1931

EIDD-1619
T31608-10mg 10mg Ask for price
Description: EIDD-1619

EIDD-1619
T31608-1g 1g Ask for price
Description: EIDD-1619

EIDD-1619
T31608-1mg 1mg Ask for price
Description: EIDD-1619

EIDD-1619
T31608-50mg 50mg Ask for price
Description: EIDD-1619